These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24814705)

  • 21. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.
    Llop E; Ferrer-Batallé M; Barrabés S; Guerrero PE; Ramírez M; Saldova R; Rudd PM; Aleixandre RN; Comet J; de Llorens R; Peracaula R
    Theranostics; 2016; 6(8):1190-204. PubMed ID: 27279911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
    Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.
    Meany DL; Zhang Z; Sokoll LJ; Zhang H; Chan DW
    J Proteome Res; 2009 Feb; 8(2):613-9. PubMed ID: 19035787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structure of human prostate-specific antigen in a sandwich antibody complex.
    Stura EA; Muller BH; Bossus M; Michel S; Jolivet-Reynaud C; Ducancel F
    J Mol Biol; 2011 Dec; 414(4):530-44. PubMed ID: 22037582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL.
    Hsieh PF; Chang CH; Yang CR; Huang CP; Chen WC; Yeh CC; Chou EC; Chen KL; Lien CS; Chen GH; Hsiao PJ; Chang YH; Wu HC
    Kaohsiung J Med Sci; 2018 Aug; 34(8):461-466. PubMed ID: 30041764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.
    Eminaga O; Bögemann M; Breil B; Titze U; Wötzel F; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Nov; 32(8):1317-26. PubMed ID: 24893699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml).
    Caliskan S
    J Cancer Res Ther; 2017; 13(2):279-283. PubMed ID: 28643748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
    Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
    Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.
    Li QK; Chen L; Ao MH; Chiu JH; Zhang Z; Zhang H; Chan DW
    Theranostics; 2015; 5(3):267-76. PubMed ID: 25553114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values.
    Yilmaz H; Ciftci S; Yavuz U; Ustuner M; Saribacak A; Dillioglugil O
    Kaohsiung J Med Sci; 2015 Jun; 31(6):315-9. PubMed ID: 26043411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
    Steuber T; Vickers A; Haese A; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2007 Apr; 120(7):1499-504. PubMed ID: 17205511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?
    Shepherd L; Borges ÁH; Ravn L; Harvey R; Bower M; Grulich A; Silverberg M; Kronborg G; Galli M; Kirk O; Lundgren J; Mocroft A;
    Antivir Ther; 2016; 21(6):529-534. PubMed ID: 26823399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
    Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
    BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL.
    Babaian RJ; Fritsche H; Ayala A; Bhadkamkar V; Johnston DA; Naccarato W; Zhang Z
    Urology; 2000 Dec; 56(6):1000-6. PubMed ID: 11113747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.